Skip to content

Trulieve Cannabis

US · TRLV #2769 by market cap Listed 1970
8.68 -0.67 -7.17%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:55

Valuation each multiple against its own 5-year range

P/B ratio 2.73 Expensive vs history 84th percentile
5-year average 1.54 · #46 of 68 in Drug Manufacturers - Specialty & Generic
P/E ratio -4.72 In line with history 35th percentile
5-year average 0.66 · forward 31.12
P/S ratio 1.95 Expensive vs history 68th percentile
5-year average 1.87 · forward 2.22 · #35 of 78 in Drug Manufacturers - Specialty & Generic

Vs. peers Drug Manufacturers - Specialty & Generic

Company Market cap P/E (TTM) P/B Div yield
Trulieve Cannabis (TRLV) 1.68B -3.76 2.17 0.00%
Takeda Pharmaceutical (TAK) 69.76B 311.00 1.50 1.44%
Teva Pharmaceutical Industries (TEVA) 45.77B 91.23 5.74 0.00%
Haleon (HLN) 39.76B 19.14 1.85 2.09%
Zoetis (ZTS) 32.14B 13.34 9.73 2.64%
United Therapeutics (UTHR) 23.63B 20.94 3.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value12.50 Economic moatNone UncertaintyHigh

Trading 44.0% below Morningstar's fair value estimate.

Fair value

Trulieve Cannabis Corp is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 13% discount to our quantitative fair value estimate of $12.50 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The company's balance sheet strengthens our valuation estimate. Low leverage mitigates financial risk, potentially boosting a firm's value. For example, the firm's current ratio of 5.5 sits in the top 10% globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are cheap.

Alternatively, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of -5.5%, a core component of profitability, lies in the bottom 20% compared with peers globally. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:55:00 · For reference only, not investment advice and not tailored to your situation.

Trulieve Cannabis discussion 0 comments

Add a comment